The Series C round financing will be used to fund a phase 3 trial of its lead drug, SER-109, intended to prevent the recurrence of Clostridium difficile infection. The drug is considered a biologic by the U.S. Food and Drug Administration. Early stage trial results showed that the use of the drug resulted in 29 out of 30 patients remaining infection-free for two months, according to the report.
More articles on gastroenterology:
ASGE, ACG update GI procedure quality indicators: 4 things to know
FDA approves Aer-O-Scope Colonoscope System
4 gastroenterologists on the move
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
